OncRef

Clinical Trial: NCT02411448

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 3

Lead Sponsor:Eli Lilly and Company
Information Provided By:Eli Lilly and Company
Last Update Posted:2026-10-06

Study Overview

Brief Summary

The main purpose of this study is to evaluate the efficacy and safety of ramucirumab in combination with erlotinib as compared to placebo in combination with erlotinib in previously untreated participants with stage IV non-small cell lung cancer (NSCLC) harboring an activating epidermal growth factor receptor (EGFR) mutation (Exon 19-Del and Exon 21 L858R). Safety and tolerability of ramucirumab in combination with erlotinib will be assessed in Part A before proceeding to Part B.

The purpose of Part C is to determine the efficacy and safety of ramucirumab in combination with gefitinib in previously untreated East Asian participants with EGFR mutation-positive metastatic NSCLC and of ramucirumab in combination with osimertinib in those participants whose disease progressed on ramucirumab and gefitinib and that have T790M - positive metastatic NSCLC.

Official Title

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer

Conditions

Metastatic Non-Small Cell Lung Cancer

Intervention / Treatment

  • Drug: Ramucirumab
  • Drug: Placebo
  • Drug: Erlotinib
  • Drug: Gefitinib
  • Drug: Osimertinib

Other Study ID Numbers

  • 15540
  • I4T-MC-JVCY
  • 2014-004824-22
  • 2014

Start Date (Actual)

2015-05-06

Primary Completion Date (Actual)

2019-01-23

Study Completion Date (Estimated)

2026-12

Enrollment (Actual)

545

Study Type

Interventional

Phase

Phase 3